Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Anti-androgen Drug MDV3100 Significantly Improves OS in PIII AFFIRM Trial: Astellas
November 4, 2011
- Complaints of Side Effects from Lyrica Up Sharply: Nextit Research
November 4, 2011
- Santen Reports Steady 5.3% Increase in Sales in Domestic, Overseas Markets in Apr-Sep
November 2, 2011
- Eisai President Says Japan, China to Become Key Battlefields for Aricept
November 2, 2011
- Bayer Yakuhin to Reorganize Structure, Offer Early Retirement Program to 150
November 2, 2011
- AstraZeneca’s 9-Month Global Sales Fell Due to Competition with Generics
November 2, 2011
- Profits Show Double-Digit Drop Due to Increased R&D Costs: Torii
November 2, 2011
- Daiichi Sankyo Suspends PII Trials in US, Europe for Post-Surgery VTE Prevention
November 2, 2011
- Shionogi Aiming for US Launch of Vaginal Atrophy Treatment Ospemifene in 2013
November 2, 2011
- Marketing of Imusera, Telavic to Be Limited to Specialists at First: MTPC
November 2, 2011
- Daiichi Sankyo Reports Decreases in Sales, Profits in Apr-Sept Term by Slump of Ranbaxy, Return of Marketing Rights
November 1, 2011
- MTPC: Profits Down but Remicade, Generics Show Steady Growth in Apr-Sept
November 1, 2011
- DSP to Boost Domestic CNS Business for Early Maximization of Lonasen
November 1, 2011
- Shionogi’s Strength in Japan Weakened by Slack US Results, Overall Sales Down 13.5% in Apr-Sept
November 1, 2011
- Sharp Decrease in Profits due to Declines in License Revenues: JCR’s Half year Financial Report
November 1, 2011
- Zeria Upwardly Revises Profits forecasts for 1st Half of FY2012
November 1, 2011
- Mochida: Epadel, Lexapro Drive Growth in 1st-Half Sales and Profits
November 1, 2011
- DSP: Strong Yen Contributes to 5.6% Decline in Sales
November 1, 2011
- Further Deterioration in Sales Prices Unlikely in 2nd Half: President Watanabe of Mediceo
November 1, 2011
- Three Top Dispensing Pharmacy Chains Report 50% Growth in Operating Profits
November 1, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…